Italia markets open in 5 hours 33 minutes

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
39.177,33
+107,65(+0,28%)
EUR/USD
1,0862
+0,0001(+0,01%)
Bitcoin EUR
65.153,59
+4.045,21(+6,62%)
CMC Crypto 200
1.514,15
+159,73(+11,79%)

NBIX May 2024 175.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,3300

0,0000

(0,00%)

In data: 03:46PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat